Triple Negative Breast Neoplasms: Clinical Trials

1,202 trials for Triple Negative Breast Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

303 recruiting, 299 completed, 153 terminated, 146 active not recruiting. 606 Phase 2, 463 Phase 1, 100 Phase 3, 72 Not applicable, 25 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2606Recruiting 158, Completed 135, Terminated 88, Unknown 79, Active not recruiting 63, Not yet recruiting 58, Withdrawn 24, Enrolling by invitation 1
Phase 1463Completed 145, Recruiting 105, Terminated 86, Active not recruiting 61, Unknown 29, Not yet recruiting 17, Withdrawn 16, Suspended 3, Enrolling by invitation 1
Phase 3100Completed 25, Recruiting 25, Active not recruiting 21, Not yet recruiting 10, Unknown 9, Terminated 6, Suspended 2, Enrolling by invitation 1, Withdrawn 1
Not applicable72Recruiting 25, Active not recruiting 12, Not yet recruiting 10, Completed 9, Withdrawn 9, Unknown 4, Terminated 2, Suspended 1
Early Phase 125Recruiting 9, Completed 7, Withdrawn 4, Active not recruiting 2, Terminated 2, Unknown 1
Phase 46Unknown 3, Recruiting 2, Not yet recruiting 1

Follow Triple Negative Breast Neoplasms: new trials by email Literature Review of Triple Negative Breast Neoplasms trials Research Report on Triple Negative Breast Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.
Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly - Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer
Phase 2Not yet recruitingThe University of The West Indies7502027-06-012026-09-22
Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
[18F]FMISO-PET with contrast-enhanced MRI - Triple Negative Breast Cancer
Early Phase 1RecruitingUniversity of Alabama at Birmingham202027-06-012026-08-17
TROPION Breast Respond in 1L TNBC
Dato-DXd - Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
Not yet recruitingDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company4002027-03-012026-10-09
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
Neoadjuvant Chemotherapy, Radiation Therapy, MRI - Breast Cancer, HER2-positive Breast Cancer
Phase 1 / Phase 2Not yet recruitingOhio State University Comprehensive Cancer Center842027-01-152026-11-09
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
Carboplatin, Paclitaxcel, Pembrolizumab - Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
Phase 2RecruitingMedical University of South Carolina552027-01-012026-10-15
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
BLEX 404 Oral Liquid - Triple Negative Breast Cancer
Phase 1 / Phase 2Not yet recruitingBioLite, Inc.442027-01-012026-04-13
Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
Cromolyn, TQB2102, and Panpulimab - Triple -Negative Breast Cancer
Phase 2Not yet recruitingFudan University462027-01-012026-09-25
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 2Not yet recruitingEmory University322027-01-012026-11-04
Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC
AI-analysis on diagnostic and surgical specimens - Triple Negative Breast Cancer
Not yet recruitingInstitute of Cancer Research, United Kingdom502026-12-012026-11-04
Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
Paclitaxel, Carboplatin, Pembrolizumab - Triple Negative Breast Cancer
Phase 1Not yet recruitingWashington University School of Medicine302026-12-012026-11-05
Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery
BCS + SRG-514, BCS - TNBC - Triple-Negative Breast Cancer
Phase 3Not yet recruitingSURGE Therapeutics4002026-12-012026-11-12
A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer
Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043, Investigator's Choice of Chemotherapy (paclitaxel,nab paclitaxel,capecitabine,eribulin,carboplatin) - Triple Negative Breast Cancer
Phase 3Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.5502026-11-302026-10-19
Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer
Dexamethasone, Famotidine, Diphenhydramine - Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC)
Phase 2Not yet recruitingWashington University School of Medicine172026-11-302026-11-03
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Arm 1 - Breast Cancer, Breast Carcinoma
RecruitingNational Cancer Institute (NCI)1392026-11-182026-11-13
Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.
Triple Negative Breast Cancer (TNBC), Early Setting
Not yet recruitingBarts & The London NHS Trust3002026-11-132026-04-27
Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment
Thymalfasin - Breast Cancer, TNBC - Triple-Negative Breast Cancer
Phase 2Not yet recruitingFudan University5722026-11-082026-10-20
Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial
Paclitaxel + Carboplatin, Pembrolizumab - Triple Negative Breast Cancer, Blood and Image Guided
Phase 2Not yet recruitingM.D. Anderson Cancer Center2002026-11-052026-05-28
Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer
Non interventional study - Breast Cancer (Triple Negative Breast Cancer (TNBC))
Not yet recruitingAssistance Publique - Hôpitaux de Paris1002026-11-012026-07-07
Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer
Pembrolizumab - Early Triple-Negative Breast Cancer
Phase 2Not yet recruitingInstitut Paoli-Calmettes842026-11-012026-10-05
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 2Not yet recruitingUniversity of Washington602026-11-012026-10-16

Showing 20 of 1202. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (470)  ·  Carcinoma, Non-Small-Cell Lung (197)  ·  Ovarian Neoplasms (135)  ·  Squamous Cell Carcinoma of Head and Neck (103)  ·  Neoplasm Metastasis (94)  ·  Colorectal Neoplasms (91)  ·  Melanoma (90)  ·  Carcinoma, Renal Cell (83)  ·  Endometrial Neoplasms (76)  ·  Stomach Neoplasms (75)  ·  Neoplasms (74)  ·  Uterine Cervical Neoplasms (69)  ·  Pancreatic Neoplasms (58)  ·  Small Cell Lung Carcinoma (58)

Broader conditions

Skin and Connective Tissue Diseases (1202)  ·  Skin Diseases (1201)  ·  Breast Diseases (1199)  ·  Neoplasms by Site (1199)  ·  Neoplasms (1128)  ·  Breast Neoplasms (732)  ·  Neoplasms by Histologic Type (252)  ·  Urogenital Diseases (235)  ·  Urogenital Neoplasms (232)  ·  Female Urogenital Diseases (230)  ·  Female Urogenital Diseases and Pregnancy Complications (230)  ·  Respiratory Tract Neoplasms (230)  ·  Respiratory Tract Diseases (229)  ·  Thoracic Neoplasms (229)  ·  Lung Diseases (228)

Interventions

pembrolizumab (173)  ·  Carboplatin (152)  ·  Paclitaxel (130)  ·  Cyclophosphamide (97)  ·  130-nm albumin-bound paclitaxel (68)  ·  Capecitabine (67)  ·  Doxorubicin (54)  ·  Gemcitabine (54)  ·  Albumin-Bound Paclitaxel (45)  ·  Taxes (42)  ·  Cisplatin (41)  ·  atezolizumab (41)  ·  sacituzumab govitecan (35)  ·  Nivolumab (34)  ·  Epirubicin (33)

Sponsors

Fudan University (63)  ·  National Cancer Institute (NCI) (45)  ·  M.D. Anderson Cancer Center (28)  ·  Novartis Pharmaceuticals (21)  ·  AstraZeneca (14)  ·  Merck Sharp & Dohme LLC (14)  ·  City of Hope Medical Center (11)  ·  Gilead Sciences (11)  ·  Pfizer (11)  ·  AbbVie (10)  ·  Hoffmann-La Roche (10)  ·  Mayo Clinic (10)  ·  Memorial Sloan Kettering Cancer Center (10)  ·  Sun Yat-sen University (10)  ·  Chinese Academy of Medical Sciences (9)

Countries

United States (640)  ·  China (243)  ·  Spain (135)  ·  France (124)  ·  Canada (96)  ·  United Kingdom (94)  ·  Australia (93)  ·  Italy (93)  ·  South Korea (74)  ·  Belgium (65)  ·  Germany (62)  ·  Japan (60)  ·  Taiwan (52)  ·  Israel (36)  ·  Poland (35)

Top investigators

Priyanka Sharma, MD (6)  ·  Clinton Yam (5)  ·  Kari Wisinski, MD (5)  ·  David Page, MD (4)

Results publications

PMID 32450725, PMID 32101663, PMID 24529560, PMID 25092775, PMID 30345906, PMID 32379297, PMID 32966830, PMID 19299237, PMID 25349301, PMID 27872127, PMID 28564564, PMID 29501363, PMID 33278935, PMID 34037241, PMID 34173924, PMID 35042534, PMID 35728046, PMID 35857659, PMID 38979716, PMID 39302614, PMID 39558017, PMID 40443562, PMID 16011702, PMID 16077072, PMID 17135638, PMID 17438091, PMID 17641361, PMID 17785706, PMID 17991697, PMID 18258986, PMID 19097774, PMID 19487376, PMID 19647220, PMID 19917869, PMID 20157582, PMID 20304629, PMID 20404251, PMID 20556505, PMID 20586616, PMID 20872150, PMID 21208101, PMID 21304525, PMID 21383283, PMID 21437909, PMID 21483002, PMID 21633166, PMID 21671016, PMID 21708823, PMID 21796368, PMID 21818123

NIH funding

2023 (25), 2016 (23), 2017 (16), 2019 (16), 2018 (15), 2014 (11), 2025 (8), UM1CA186709 (8), 2015 (5), P30CA016672 (5), P30CA068485 (5), P30CA138292 (5), P30CA033572 (4), UM1CA186689 (4), UM1CA186704 (4)